| Name | Odronextamab |
| Synonyms | Odronextamab |
| CAS | 1801338-64-6 |
| antibody | onitumumab/Odronextamab is a hinge-stable, fully humanized IgG4 type CD20 × CD3 bispecific antibody, which can bind CD3 on T cells and CD20 on B cells. In order to evaluate the safety and anti-tumor activity of Odronextamab in patients with relapsed or refractory B- cell non-Hodgkin's lymphoma, this single-arm, multi-center, phase I dose-escalation and dose-expansion study (ELM-1) enrolled such patients in 10 academic centers in the United States and Germany. |
| biological activity | human CD20 × CD3 bispecific antibody onitumumab (REGN1979) can induce a long-lasting and complete response in patients with highly refractory B- cell non-Hodgkin's lymphoma (including patients who are ineffective in chimeric antigen receptor T cell therapy (CAR-T)). |